Immunotherapy before surgery for stage II-IIIA lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether two immunotherapy drugs (nivolumab and ipilimumab) given before surgery can help treat non-small cell lung cancer that is stage II to IIIA. It's for people whose tumors are removable and who haven't had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that does not have EGFR or ALK gene changes.
- Your cancer is stage II to IIIA and can be removed with surgery.
- You have not had chemotherapy or radiation for this cancer before.
- You have good overall health status (able to do daily activities like walking and self-care).
- You do not have active autoimmune disease or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.